Patents by Inventor Rie Ishida
Rie Ishida has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210077491Abstract: The present invention addresses the problem of providing a pharmaceutical composition for the prevention and/or treatment of diseases related to pulmonary fibrosis. Provided is a pharmaceutical composition for the prevention and/or treatment of diseases involving pulmonary fibrosis, in which the active ingredient is 3-[2-(5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-propyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl)phenyl]-1,2,4-oxadiazol-5(4H)-one, or a salt thereof, or a solvate of these.Type: ApplicationFiled: December 14, 2018Publication date: March 18, 2021Applicant: Kowa Company, Ltd.Inventors: Kentaro Mikami, Rie Ishida, Takashi Nakagawa
-
Publication number: 20200390766Abstract: [Problem to be solved] The present invention addresses the problem of providing a pharmaceutical composition for the prevention and/or treatment of diseases related to pulmonary fibrosis. [Solution] Provided is a pharmaceutical composition for the prevention and/or treatment of diseases involving pulmonary fibrosis, in which the active ingredient is 3-[2-(5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-propyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl)phenyl]-1,2,4-oxadiazol-5(4H)-one, or a salt thereof, or a solvate of these.Type: ApplicationFiled: June 12, 2020Publication date: December 17, 2020Inventors: Kentaro Mikami, Rie Ishida, Takashi Nakagawa
-
Patent number: 9315493Abstract: The present invention provides: a compound represented by general formula (I) below, that has both angiotensin II receptor antagonism and a PPAR? activation effect and that is useful as a preventative and/or therapeutic agent for high blood pressure, cardiac disease, arteriosclerosis, type-2 diabetes, and the like; and a drug composition containing the compound. General formula (I) (in the formula: ring A represents a pyridine ring; ring B represents a tetrazole ring or an oxadiazol-5(4H)-one ring; X represents C—R5 or a nitrogen atom; R1 represents an alkyl group; R2 represents an alkyl group or a cycloalkyl group; and R3, R4, and R5 each independently represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group or similar.Type: GrantFiled: March 13, 2012Date of Patent: April 19, 2016Assignee: KOWA COMPANY, LTD.Inventors: Toru Miura, Seiichi Sato, Hajime Yamada, Junya Tagashira, Toshiaki Watanabe, Ryohei Sekimoto, Rie Ishida, Hitomi Aoki, Tadaaki Ohgiya
-
Patent number: 8778954Abstract: Disclosed are: a novel compound which has both an antagonistic activity on an angiotensin II receptor and a PPAR?-activating activity and is therefore useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, arteriosclerosis, type-2 diabetes, diabetic complications, metabolic syndrome or the like; and a pharmaceutical composition containing the compound.Type: GrantFiled: September 29, 2010Date of Patent: July 15, 2014Assignee: Kowa Company, Ltd.Inventors: Toru Miura, Seiichi Sato, Hajime Yamada, Junya Tagashira, Ryohei Sekimoto, Rie Ishida, Hitomi Aoki, Tadaaki Ohgiya
-
Patent number: 8664226Abstract: Disclosed is a compound which has both an angiotensin-II receptor antagonistic activity and a PPAR? activation activity and is useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, angina pectoris, cerebrovascular disorders, cerebral circulatory disorders, ischemic peripheral circulatory disorders, renal diseases, arteriosclerosis, inflammatory diseases, type-2 diabetes, diabetic complications, insulin resistance syndrome, syndrome X, metabolic syndrome and hyperinsulinemia. [In the formula, A represents a 5- to 10-membered heteroaryl group; R1 and R2 independently represent a C1-6 alkyl group; and each of R3 to R5 is absent or represents H, a halogen atom, OH, NO2, a halo-C1-6 alkyl group, a (substituted) C1-6 alkoxy group, a (substituted) C3-6 cycloalkyloxy group, or a 5- to 10-membered heteroaryl group.Type: GrantFiled: April 16, 2010Date of Patent: March 4, 2014Assignee: Kowa Company, Ltd.Inventors: Toru Miura, Kazuhiro Onogi, Seiichi Sato, Junya Tagashira, Gen Watanabe, Ryohei Sekimoto, Rie Ishida, Hitomi Aoki, Tadaaki Ohgiya
-
Publication number: 20140011823Abstract: The present invention provides: a compound represented by general formula (I) below, that has both angiotensin II receptor antagonism and a PPAR? activation effect and that is useful as a preventative and/or therapeutic agent for high blood pressure, cardiac disease, arteriosclerosis, type-2 diabetes, and the like; and a drug composition containing the compound. General formula (I) (in the formula: ring A represents a pyridine ring; ring B represents a tetrazole ring or an oxadiazol-5(4H)-one ring; X represents C—R5 or a nitrogen atom; R1 represents an alkyl group; R2 represents an alkyl group or a cycloalkyl group; and R3, R4, and R5 each independently represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group or similar.Type: ApplicationFiled: March 13, 2012Publication date: January 9, 2014Applicant: KOWA COMPANY, LTD.Inventors: Toru Miura, Seiichi Sato, Hajime Yamada, Junya Tagashira, Toshiaki Watanabe, Ryohei Sekimoto, Rie Ishida, Hitomi Aoki, Tadaaki Ohgiya
-
Publication number: 20120322819Abstract: Disclosed is novel compound and medicinal formulation containing same, possessing both angiotensin II receptor blocking and PPAR? activation effect, of use as a medicine for prevention and/or treatment of hypertension, heart disease, angina pectoris, cerebrovascular disorder, cerebral circulatory disturbances, post-ischemic peripheral circulatory damage, renal disease, arteriosclerosis, inflammatory disorder, type 2 diabetes, diabetic complications, insulin resistance syndrome, syndrome X, metabolic syndrome and hyperinsulinaemia. Further disclosed is the general formula I (where one or both of R1 and R2 represent a C1-6 alkyl group, R3 represents a C1-6 alkyl group which may contain one or more substituent groups selected from group A, or a C3-8 cycloalkyl group which may contain one or more substituent groups selected from group B.) which represents the compound, and salts thereof, solvates thereof, and medicinal compositions containing any of these.Type: ApplicationFiled: February 25, 2011Publication date: December 20, 2012Applicant: KOWA COMPANY, LTD.Inventors: Toru Miura, Kazuhiro Onogi, Junya Tagashira, Gen Watanabe, Ryohei Sekimoto, Rie Ishida, Hitomi Aoki, Tadaaki Ohgiya
-
Publication number: 20120264753Abstract: Disclosed is a novel 1-(biphenyl-4-yl-methyl)-1H-imidazole derivative represented by general formula (I), which has both angiotensin II receptor antagonist activity and PPAR-? activating activity and is useful as a prophylactic and/or therapeutic agent for cardiovascular diseases and metabolic diseases. Also disclosed is a pharmaceutical composition which contains the novel 1-(biphenyl-4-yl-methyl)-1H-imidazole derivative. In general formula (I), ring A represents a group represented by formula (II) or (III); R1 represents a C1-6 alkyl group; R2 represents a C1-6 alkyl group which may be substituted by a hydroxy group, or a group represented by formula —CO—R4 (wherein R4 represents a hydroxy group, a C1-6 alkoxy group, an amino group, a mono(C1-6 alkyl)amino group, a di(C1-6 alkyl)amino group, a morpholino group, a piperidino group or a pyrrolidino group); R3 represents a halogen atom or a C1-6 alkoxy group; and X and Y may be the same or different and each represents a nitrogen atom or CH.Type: ApplicationFiled: December 22, 2010Publication date: October 18, 2012Applicant: KOWA COMPANY, LTD.Inventors: Toru Miura, Hajime Yamada, Junya Tagashira, Gen Watanabe, Ryohei Sekimoto, Rie Ishida, Hitomi Aoki, Tadaaki Ohgiya
-
Publication number: 20120225896Abstract: Disclosed is a novel 2-pyridone derivative represented by general formula (1), which has both angiotensin II receptor antagonist activity and PPAR-? activating activity and is useful as a prophylactic and/or therapeutic agent for cardiovascular diseases and metabolic diseases. Also disclosed is a pharmaceutical composition which contains the novel 2-pyridone derivative. In general formula (1), R1 represents a C1-6 alkyl group or a C1-6 alkoxy group; R2 represents a C1-6 alkyl group or a C3-8 cycloalkyl group; R3 represents a C1-6 alkyl group, a C6-10 aryl-C1-6 alkyl group, a C1-6 alkoxy-C1-6 alkyl group or a group represented by formula (2) (wherein A represents a nitrogen atom or CH, and R5 represents a hydrogen atom or a C1-6 alkoxy group); and R4 represents a group represented by formula (3) or (4).Type: ApplicationFiled: December 22, 2010Publication date: September 6, 2012Applicant: KOWA COMPANY, LTD.Inventors: Toru Miura, Junya Tagashira, Ryohei Sekimoto, Rie Ishida, Hitomi Aoki, Tadaaki Ohgiya
-
Publication number: 20120165353Abstract: Disclosed are: a novel compound which has both an antagonistic activity on an angiotensin II receptor and a PPAR?-activating activity and is therefore useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, arteriosclerosis, type-2 diabetes, diabetic complications, metabolic syndrome or the like; and a pharmaceutical composition containing the compound.Type: ApplicationFiled: September 29, 2010Publication date: June 28, 2012Applicant: KOWA COMPANY, LTD.Inventors: Toru Miura, Seiichi Sato, Hajime Yamada, Junya Tagashira, Ryohei Sekimoto, Rie Ishida, Hitomi Aoki, Tadaaki Ohgiya
-
Publication number: 20120046308Abstract: An ?-phenoxybenzeneacetic acid derivative represented by general formula (I), which has both an angiotensin II receptor antagonistic activity and a PPAR? activation activity and is useful as a prophylactic and/or therapeutic agent for hypertension, metabolic syndrome or the like, a salt of the derivative, or a solvate of the derivative or the salt; and a pharmaceutical composition containing the derivative, the salt or the solvate.Type: ApplicationFiled: May 28, 2010Publication date: February 23, 2012Applicant: KOWA COMPANY, LTD.Inventors: Toru Miura, Kazuhiro Onogi, Junya Tagashira, Gen Watanabe, Ryohei Sekimoto, Rie Ishida, Hitomi Aoki, Tadaaki Ohgiya
-
Publication number: 20120028983Abstract: Disclosed is a compound which has both an angiotensin-II receptor antagonistic activity and a PPAR? activation activity and is useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, angina pectoris, cerebrovascular disorders, cerebral circulatory disorders, ischemic peripheral circulatory disorders, renal diseases, arteriosclerosis, inflammatory diseases, type-2 diabetes, diabetic complications, insulin resistance syndrome, syndrome X, metabolic syndrome and hyperinsulinemia. [In the formula, A represents a 5- to 10-membered heteroaryl group; R1 and R2 independently represent a C1-6 alkyl group; and each of R3 to R5 is absent or represents H, a halogen atom, OH, NO2, a halo-C1-6 alkyl group, a (substituted) C1-6 alkoxy group, a (substituted) C3-6 cycloalkyloxy group, or a 5- to 10-membered heteroaryl group.Type: ApplicationFiled: April 16, 2010Publication date: February 2, 2012Applicant: KOWA COMPANY, LTD.Inventors: Toru Miura, Kazuhiro Onogi, Seiichi Sato, Junya Tagashira, Gen Watanabe, Ryohei Sekimoto, Rie Ishida, Hitomi Aoki, Tadaaki Ohgiya
-
Publication number: 20110306623Abstract: Provided are novel compounds that have both angiotensin II receptor-antagonist effects and PPAR-activating effects that are useful as agents for preventing and/or treating hypertension, heart disease, angina, cerebral vascular accident, cerebrovascular disorder, ischemic peripheral circulatory disorder, kidney disease, atherosclerosis, inflammatory disease, type 2 diabetes mellitus, diabetic complication, insulin resistance syndrome, Syndrome X, metabolic syndrome, and hyperinsulinemia.Type: ApplicationFiled: February 22, 2010Publication date: December 15, 2011Applicant: KOWA COMPANY, LTD.Inventors: Toru Miura, Kazuhiro Onogi, Junya Tagashira, Gen Watanabe, Ryohei Sekimoto, Rie Ishida, Tadaaki Ohgiya